Lack of In Vitro and In Vivo Recognition of Francisella tularensis Subspecies Lipopolysaccharide by Toll-Like Receptors
- 1 December 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (12) , 6730-6738
- https://doi.org/10.1128/iai.00934-06
Abstract
Francisella tularensis is an intracellular gram-negative bacterium that is highly infectious and potentially lethal. Several subspecies exist of varying pathogenicity. Infection by only a few organisms is sufficient to cause disease depending on the model system. Lipopolysaccharide (LPS) of gram-negative bacteria is generally recognized by Toll-like receptor 4 (TLR4)/MD-2 and induces a strong proinflammatory response. Examination of human clinical F. tularensis isolates revealed that human virulent type A and type B strains produced lipid A of similar structure to the nonhuman model pathogen of mice, Francisella novicida. F. novicida LPS or lipid A is neither stimulatory nor an antagonist for human and murine cells through TLR4 or TLR2. It does not appear to interact with TLR4 or MD-2, as it is not an antagonist to other stimulatory LPS. Consistent with these observations, aerosolization of F. novicida LPS or whole bacteria induced no inflammatory response in mice. These results suggest that poor innate recognition of F. tularensis allows the bacterium to evade early recognition by the host innate immune system to promote its pathogenesis for mammals.Keywords
This publication has 47 references indexed in Scilit:
- Basis for the Failure ofFrancisella tularensisLipopolysaccharide To Prime Human Polymorphonuclear LeukocytesInfection and Immunity, 2006
- LPS, TLR4 and infectious disease diversityNature Reviews Microbiology, 2005
- Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxinAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agentsExpert Opinion on Biological Therapy, 2004
- Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerizationInternational Immunology, 2004
- Will the enigma of Francisella tularensis virulence soon be solved?Trends in Microbiology, 2003
- Lipopolysaccharide EndotoxinsAnnual Review of Biochemistry, 2002
- Human Toll-like receptor 4 recognizes host-specific LPS modificationsNature Immunology, 2002
- Invited review: Bacterial lipopolysaccharides and innate immunityInnate Immunity, 2001
- Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of VaccinesMethods, 1999